177 related articles for article (PubMed ID: 19360338)
1. Human precision-cut liver tumor slices as a tumor patient-individual predictive test system for oncolytic measles vaccine viruses.
Zimmermann M; Armeanu S; Smirnow I; Kupka S; Wagner S; Wehrmann M; Rots MG; Groothuis GM; Weiss TS; Königsrainer A; Gregor M; Bitzer M; Lauer UM
Int J Oncol; 2009 May; 34(5):1247-56. PubMed ID: 19360338
[TBL] [Abstract][Full Text] [Related]
2. Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma.
Blechacz B; Splinter PL; Greiner S; Myers R; Peng KW; Federspiel MJ; Russell SJ; LaRusso NF
Hepatology; 2006 Dec; 44(6):1465-77. PubMed ID: 17133484
[TBL] [Abstract][Full Text] [Related]
3. An armed oncolytic measles vaccine virus eliminates human hepatoma cells independently of apoptosis.
Lampe J; Bossow S; Weiland T; Smirnow I; Lehmann R; Neubert W; Bitzer M; Lauer UM
Gene Ther; 2013 Nov; 20(11):1033-41. PubMed ID: 23719065
[TBL] [Abstract][Full Text] [Related]
4. Retargeted oncolytic measles strains entering via the EGFRvIII receptor maintain significant antitumor activity against gliomas with increased tumor specificity.
Allen C; Vongpunsawad S; Nakamura T; James CD; Schroeder M; Cattaneo R; Giannini C; Krempski J; Peng KW; Goble JM; Uhm JH; Russell SJ; Galanis E
Cancer Res; 2006 Dec; 66(24):11840-50. PubMed ID: 17178881
[TBL] [Abstract][Full Text] [Related]
5. Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specific CD8 response.
Gauvrit A; Brandler S; Sapede-Peroz C; Boisgerault N; Tangy F; Gregoire M
Cancer Res; 2008 Jun; 68(12):4882-92. PubMed ID: 18559536
[TBL] [Abstract][Full Text] [Related]
6. Preclinical testing of virotherapeutics for primary and secondary tumors of the liver.
Zimmermann M; Weiland T; Bitzer M; Lauer UM
Methods Mol Biol; 2012; 806():121-36. PubMed ID: 22057449
[TBL] [Abstract][Full Text] [Related]
7. Enhanced killing of ovarian carcinoma using oncolytic measles vaccine virus armed with a yeast cytosine deaminase and uracil phosphoribosyltransferase.
Hartkopf AD; Bossow S; Lampe J; Zimmermann M; Taran FA; Wallwiener D; Fehm T; Bitzer M; Lauer UM
Gynecol Oncol; 2013 Aug; 130(2):362-8. PubMed ID: 23676551
[TBL] [Abstract][Full Text] [Related]
8. Liver cancer protease activity profiles support therapeutic options with matrix metalloproteinase-activatable oncolytic measles virus.
Mühlebach MD; Schaser T; Zimmermann M; Armeanu S; Hanschmann KM; Cattaneo R; Bitzer M; Lauer UM; Cichutek K; Buchholz CJ
Cancer Res; 2010 Oct; 70(19):7620-9. PubMed ID: 20858718
[TBL] [Abstract][Full Text] [Related]
9. Oncolytic vesicular stomatitis virus for treatment of orthotopic hepatocellular carcinoma in immune-competent rats.
Ebert O; Shinozaki K; Huang TG; Savontaus MJ; García-Sastre A; Woo SL
Cancer Res; 2003 Jul; 63(13):3605-11. PubMed ID: 12839948
[TBL] [Abstract][Full Text] [Related]
10. Advantages of using recombinant measles viruses expressing a fluorescent reporter gene with vibratome slice technology in experimental measles neuropathogenesis.
Ludlow M; Duprex WP; Cosby SL; Allen IV; McQuaid S
Neuropathol Appl Neurobiol; 2008 Aug; 34(4):424-34. PubMed ID: 17986184
[TBL] [Abstract][Full Text] [Related]
11. Primary resistance phenomena to oncolytic measles vaccine viruses.
Noll M; Berchtold S; Lampe J; Malek NP; Bitzer M; Lauer UM
Int J Oncol; 2013 Jul; 43(1):103-12. PubMed ID: 23612727
[TBL] [Abstract][Full Text] [Related]
12. Oncolytic activities of approved mumps and measles vaccines for therapy of ovarian cancer.
Myers R; Greiner S; Harvey M; Soeffker D; Frenzke M; Abraham K; Shaw A; Rozenblatt S; Federspiel MJ; Russell SJ; Peng KW
Cancer Gene Ther; 2005 Jul; 12(7):593-9. PubMed ID: 15746945
[TBL] [Abstract][Full Text] [Related]
13. Selective in vitro cytotoxic effect of human cancer cells by bluetongue virus-10.
Hu J; Dong CY; Li JK; Chen DE; Liang K; Liu J
Acta Oncol; 2008; 47(1):124-34. PubMed ID: 17851866
[TBL] [Abstract][Full Text] [Related]
14. Modeling of cancer virotherapy with recombinant measles viruses.
Bajzer Z; Carr T; Josić K; Russell SJ; Dingli D
J Theor Biol; 2008 May; 252(1):109-22. PubMed ID: 18316099
[TBL] [Abstract][Full Text] [Related]
15. Enhanced sensitivity of hepatocellular carcinoma cells to chemotherapy with a Smac-armed oncolytic adenovirus.
Pan QW; Zhong SY; Liu BS; Liu J; Cai R; Wang YG; Liu XY; Qian C
Acta Pharmacol Sin; 2007 Dec; 28(12):1996-2004. PubMed ID: 18031615
[TBL] [Abstract][Full Text] [Related]
16. Considerations for intravascular administration of oncolytic herpes virus for the treatment of multiple liver metastases.
Nomura N; Kasuya H; Watanabe I; Shikano T; Shirota T; Misawa M; Sugimoto H; Kanazumi N; Nomoto S; Takeda S; Nakao A
Cancer Chemother Pharmacol; 2009 Jan; 63(2):321-30. PubMed ID: 18575868
[TBL] [Abstract][Full Text] [Related]
17. Persistent measles virus infection of mouse neural cells lacking known human entry receptors.
Abdullah H; Earle JA; Gardiner TA; Tangy F; Cosby SL
Neuropathol Appl Neurobiol; 2009 Oct; 35(5):473-86. PubMed ID: 19490430
[TBL] [Abstract][Full Text] [Related]
18. Pulsed versus continuous application of the prodrug 5-fluorocytosine to enhance the oncolytic effectiveness of a measles vaccine virus armed with a suicide gene.
Yurttas C; Berchtold S; Malek NP; Bitzer M; Lauer UM
Hum Gene Ther Clin Dev; 2014 Jun; 25(2):85-96. PubMed ID: 24933569
[TBL] [Abstract][Full Text] [Related]
19. Non-invasive in vivo monitoring of trackable viruses expressing soluble marker peptides.
Peng KW; Facteau S; Wegman T; O'Kane D; Russell SJ
Nat Med; 2002 May; 8(5):527-31. PubMed ID: 11984600
[TBL] [Abstract][Full Text] [Related]
20. Passage in Vero cells alters the characteristics of measles AIK-C vaccine strain.
Uejima H; Nakayama T; Komase K
Vaccine; 2006 Feb; 24(7):931-6. PubMed ID: 16176848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
